As the new Democratic majority in the House gets ready to conduct sweeping oversight of the Trump Administration, it faces an interesting decision on how to approach the Trump Administration’s “Blueprint” on drug pricing.
On the one hand, HHS under Secretary Alex Azar has shown a willingness to push administrative reforms aggressively, with a...






